Industry News
Biotechnology Industry News
AstraZeneca’s hypertension pill…
AstraZeneca’s hypertension pill baxdrostat lowered blood pressure by almost 10 mmHg in a phase 3 trial, the Big Pharma has revealed as it gears up to seek approval.
Roche’s hypertension med…
Roche’s hypertension med zilebesiran may have failed to hit the primary endpoint of the last in a trio of midstage studies, but the Big Pharma has insisted the data were encouraging enough to take the
Roche’s Genentech unit has…
Roche’s Genentech unit has handed over $20 million upfront for the license to Omass Therapeutics’ preclinical inflammatory bowel disease program.
Industry giants Clive Meanwell and…
Industry giants Clive Meanwell and John Maraganore have unveiled a new biotech aiming to disrupt the cardiovascular landscape with a once-annual preventive heart disease candidate and an AI risk-predicting tool.
Zydus Therapeutics has racked up a…
Zydus Therapeutics has racked up a phase 2b/3 win in primary biliary cholangitis, clearing the path to a filing to establish the company as a challenger to Gilead, Intercept Pharmaceuticals and Ipsen.
Fosun Pharma has penned its third…
Fosun Pharma has penned its third inflammatory disease pact in three weeks, plucking up China rights to a clinical-stage treatment from Accro Bioscience.
A phase 1/2 trial of BeOne…
A phase 1/2 trial of BeOne Medicines’ sonrotoclax has hit its primary endpoint, furthering the biotech’s plans to launch the first BCL2 inhibitor for use in mantle cell lymphoma.
Flagship Pioneering is boosting…
Flagship Pioneering is boosting the clinical research capabilities of its biotech fleet with a new IQVIA collaboration. The CRO giant will provide Flagship’s companies with its artificial intelligence and clinical trial technologies to enhance their
The FDA has begun considering a…
The FDA has begun considering a noninvasive liver measurement as a surrogate endpoint for certain MASH patients, a move that could speed up drug development in the space.
Plexium has raised $60.1 million,…
Plexium has raised $60.1 million, providing an infusion of cash to the recently slimmed-down protein degrader specialist three years on from its breakout year.
A phase 1 study has linked…
A phase 1 study has linked Prothena’s anti-amyloid beta antibody to a higher rate of brain swelling than rival approved drugs, hindering the biotech’s positioning in early symptomatic Alzheimer’s disease.
As obesity pioneer Novo Nordisk…
As obesity pioneer Novo Nordisk loses ground in the race for next-generation drugs, the Danish pharma giant is betting on novel RNA technology to bolster its early-stage pipeline. Novo has inked a multiyear research collaboration
Mere months after its cancer…
Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a reorganization that will see the oncology company’s Pennsylvania site wind down and 130 employees laid off,
Amylyx’s withdrawn-from-market…
Amylyx’s withdrawn-from-market Relyvrio has failed to make an impact on primary or secondary endpoints in a rare neurodegenerative disease, prompting the company to discontinue the program.
Wugen has raised $115 million,…
Wugen has raised $115 million, tapping a Fidelity-led syndicate to fund its pursuit of FDA approval for the first off-the-shelf CAR-T for T-cell malignancies. A pivotal trial is underway, putting the company on track to
Nykode Therapeutics has designed a…
Nykode Therapeutics has designed a two-year plan to turn its fortunes around. Having lost a deal with Genentech—and with the future of a Regeneron pact uncertain—the Norwegian biotech is focusing on delivering phase 2 data
Right on the heels of a similar…
Right on the heels of a similar deal, Fosun Pharma has outlicensed a second inflammatory disease candidate to a Western biotech startup.
Eight months after Sanofi’s…
Eight months after Sanofi’s former Chief Medical Officer, Dietmar Berger, M.D., departed, the French drugmaker has selected a successor.
Regeneron has reported a phase 3…
Regeneron has reported a phase 3 win in generalized myasthenia gravis, positioning the biotech to file for FDA approval of its siRNA candidate in the increasingly competitive neuromuscular disease.
The National Cancer Institute is…
The National Cancer Institute is ending its support for a 26-year-old push to advance clinical trials for children with brain tumors.